Gene Therapy Moves Forward in 2010

Por Ylä-Herttuala, Seppo
Publicado em 2011

The Need for Increased Clarity and Transparency in the Regulatory Pathway for Gene Medicines in the European Union

Por Ylä-Herttuala, Seppo
Publicado em 2012

Endgame: Glybera Finally Recommended for Approval as the First Gene Therapy Drug in the European Union

Por Ylä-Herttuala, Seppo
Publicado em 2012

From the Impact Factor to DORA and the Scientific Content of Articles

Por Ylä-Herttuala, Seppo
Publicado no Mol Ther (2015)

The Molecular Therapy Family: Past, Present, and Future

Por Ylä-Herttuala, Seppo
Publicado no Mol Ther (2015)

Glybera's Second Act: The Curtain Rises on the High Cost of Therapy

Por Ylä-Herttuala, Seppo
Publicado no Mol Ther (2015)

Gene Therapy for Heart Failure: Back to the Bench

Por Ylä-Herttuala, Seppo
Publicado no Mol Ther (2015)

ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization

Por Ylä-Herttuala, Seppo
Publicado no Mol Ther (2016)

On the relationship of LDL and VEGFR1: not just a family affair

Por Ylä-Herttuala, Seppo, Alitalo, Kari
Publicado em 2007

Does mass balance between sense and antisense transcripts fine-tune the outcome of gene expression?

Por Ylä-Herttuala, Seppo, Kaikkonen, Minna
Publicado em 2014

Molecular Therapy Special Issue on Gene Editing Technologies and Applications

Por Frederickson, Robert, Ylä-Herttuala, Seppo
Publicado no Mol Ther (2015)

Review focus on epigenetics and the histone code in vascular biology

Por Ylä-Herttuala, Seppo, Glass, Christopher K.
Publicado em 2011

Writing the Next Chapter for the Molecular Therapy Family of Journals

Por Frederickson, Robert M, Ylä-Herttuala, Seppo
Publicado no Mol Ther (2016)

Dotted collar placed around carotid artery induces asymmetric neointimal lesion formation in rabbits without intravascular manipulations

Por Kivelä, Antti, Hartikainen, Juha, Ylä-Herttuala, Seppo
Publicado em 2012

Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success

Por Dragneva, Galina, Korpisalo, Petra, Ylä-Herttuala, Seppo
Publicado em 2013

A New Gene Therapy Approach for Cardiovascular Disease by Non-coding RNAs Acting in the Nucleus

Por Husso, Tiia, Ylä-Herttuala, Seppo, Turunen, Mikko P
Publicado no Mol Ther Nucleic Acids (2014)

Differential Regulation of Vascular Endothelial Growth Factors by Promoter-targeted shRNAs

Por Laham-Karam, Nihay, Lalli, Marianne, Leinonen, Nastasia, Ylä-Herttuala, Seppo
Publicado no Mol Ther Nucleic Acids (2015)

Call for papers: Nanoparticle Development and Applications in Cellular and Molecular Therapies

Por Frederickson, Robert M., Moghimi, SM, Wagner, E, Yla-Herttuala, Seppo
Publicado no Mol Ther (2016)

Isoform-Specific Modulation of Inflammation Induced by Adenoviral Mediated Delivery of Platelet-Derived Growth Factors in the Adult Mouse Heart

Por Gallini, Radiosa, Huusko, Jenni, Ylä-Herttuala, Seppo, Betsholtz, Christer, Andrae, Johanna
Publicado no PLoS One (2016)

Screening of Complement Inhibitors: Shielded Baculoviruses Increase the Safety and Efficacy of Gene Delivery

Por Kaikkonen, Minna U, Maatta, Antti I, Ylä-Herttuala, Seppo, Airenne, Kari J
Publicado em 2010